Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Restructuring the Alpha-Gamma Code in Aging Vision

NCT: NCT07208318 · RECRUITING

NCT IDNCT07208318
StatusRECRUITING
Start Date2026-04-02
Completion2030-08-31
SponsorBoston University Charles River Campus (OTHER)
First posted
Last updated

Brief Summary

Tests whether age-related visual deficits arise from disrupted alpha-gamma coupling in visual cortex (V1) and MT. Uses fMRI, source-resolved HD-EEG, and personalized complex-waveform HD-tACS to (1) quantify aging effects on phase-amplitude coupling, (2) drive PAC into a preferred "gamma-at-alpha-troughs" state, and (3) bidirectionally change perception by aligning gamma to alpha troughs vs peaks. Two five-day, double-blind, sham-controlled studies (n=120 each) target contrast sensitivity (V1) and 3D shape-from-motion (MT), aiming for mechanistic insight and remediation in older adults with implications for ADRD.

Frequently Asked Questions

What is Restructuring the Alpha-Gamma Code in Aging Vision?

Restructuring the Alpha-Gamma Code in Aging Vision is a clinical trial registered under NCT07208318. Current status: RECRUITING.

What is the status of NCT07208318?

The current status of NCT07208318 (Restructuring the Alpha-Gamma Code in Aging Vision) is: RECRUITING.

When did Restructuring the Alpha-Gamma Code in Aging Vision start?

Restructuring the Alpha-Gamma Code in Aging Vision started on 2026-04-02.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.